AERI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AERI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aerie Pharmaceuticals's total inventories for the quarter that ended in Sep. 2022 was $46.8 Mil. Aerie Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2022 to the quarter that ended in Sep. 2022 was $46.9 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Aerie Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2022 was $-5.84.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Aerie Pharmaceuticals's Days Inventory for the three months ended in Sep. 2022 was 617.44.
Inventory Turnover measures how fast the company turns over its inventory within a year. Aerie Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Aerie Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 1.30.
The historical data trend for Aerie Pharmaceuticals's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aerie Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Total Inventories | Get a 7-Day Free Trial | - | 10.11 | 21.05 | 27.06 | 40.41 |
Aerie Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Total Inventories | Get a 7-Day Free Trial | 30.06 | 40.41 | 40.19 | 47.01 | 46.76 |
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Aerie Pharmaceuticals (NAS:AERI) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Aerie Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2022 is
Net-Net Working Capital Per Share (Q: Sep. 2022 ) | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (172.464 | + | 0.75 * 73.881 | + | 0.5 * 46.762 | - | 539.572 |
- | 0 | - | 0) | / | 49.3905 | ||
= | -5.84 |
2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Aerie Pharmaceuticals's Days Inventory for the three months ended in Sep. 2022 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Sep. 2022 ) | / | Cost of Goods Sold (Q: Sep. 2022 ) | * | Days in Period |
= | 46.8845 | / | 6.929 | * | 365 / 4 | |
= | 617.44 |
3. Inventory Turnover measures how fast the company turns over its inventory within a year.
Aerie Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Sep. 2022 ) | / | Average Total Inventories (Q: Sep. 2022 ) |
= | 6.929 | / | 46.8845 | |
= | 0.15 |
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Aerie Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as
Inventory-to-Revenue | = | Average Total Inventories (Q: Sep. 2022 ) | / | Revenue (Q: Sep. 2022 ) |
= | 46.8845 | / | 36.129 | |
= | 1.30 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Thank you for viewing the detailed overview of Aerie Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Frederick Lang | officer: Chief Financial Officer | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Raj Kannan | director, officer: Chief Executive Officer | C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451 |
Jeffrey Calabrese | officer: Vice President of Finance | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Kathleen Mcginley | officer: CHRO & VP, Corp Services | 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618 |
Christopher Staten | officer: Interim CFO | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Casey C. Kopczynski | officer: Chief Scientific Officer | 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921 |
Peter J Mcdonnell | director | 2525 DUPONT DRIVE, IRVINE CA 92612 |
Gerald D. Cagle | director | 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921 |
Foresite Capital Fund Ii, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
David Hollander | officer: Chief R&D Officer | C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Richard J Rubino | officer: Chief Financial Officer | |
Vicente Jr Anido | director, officer: Chief Executive Officer | 1621 BAYSIDE DR, CORONA DEL MAR CA 92625 |
Foresite Capital Management Iv, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Foresite Capital Fund Iv, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Thomas A Mitro | officer: President and COO | 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618 |
From GuruFocus
By Business Wire Business Wire • 04-06-2022
By Business Wire Business Wire • 08-15-2022
By GuruFocus Research GuruFocus Editor • 01-27-2023
By PurpleRose PurpleRose • 08-25-2022
By Ds*** Ds*** • 08-30-2022
By Business Wire Business Wire • 07-08-2022
By Business Wire Business Wire • 04-28-2022
By GuruFocus Research GuruFocus Editor • 02-15-2023
By PRNewswire PRNewswire • 10-17-2022
By Business Wire Business Wire • 02-24-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.